Merck pays $110m for OncoEthix and ex-Mitsubishi oncology candidate
This article was originally published in Scrip
Executive Summary
Merck & Co has acquired OncoEthix, a private Swiss oncology-focused biotechnology company, for $110m upfront and up to $265m in clinical and regulatory milestones. Merck gains an oral BET (bromodomain and extra-terminal protein) inhibitor, OTX015, which is currently in Phase I studies for the treatment of hematological malignancies and advanced solid tumors.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.